Great attention for SpectraCure in Boston
SpectraCure received a lot of attention around its clinical study results at the World Conference in Boston, attended by world leading clinical researchers.
On Wednesday, July 3rd, SpectraCure presented results from the company's phase 1 study at the 17th International Photodynamic Association World Congress in Boston, USA. Johannes Swartling, CTO of SpectraCure held the presentation after an invitation from the conference organizers. The lecture was well attended and received with great interest.
The conference was attended by a total of 450 participants. Host of the event was Professor Tayyaba Hasan, active at Harvard Medical School in Boston. Professor Hasan is also one of the inventors of verteporfin, the photosensitizing drug used by SpectraCure in combination with the company's equipment for laser light illumination of tumours, SpectraCure's P18 system with IDOSE® .
The methodology underlying SpectraCure's treatment was also noticed by the assignment of the international Photodynamic Associations finest award to Professor Avigdor Scherz, active at the Weizmann Institute, for his work in explaining the mechanisms of PDT treatment with vascular acting photosensitizing drugs, the class of drugs that includes verteporfin. "It is very pleasing that the methodology is rewarded with this price, it shows that SpectraCure's method is right in time and is considered to have good opportunities to make a real benefit to patients," comments Johannes Swartling, CTO of SpectraCure.
For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: email@example.com, phone: +46-(8)-503 000 50.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region